MY150698A - Crystalline forms of 4- [2- (-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain - Google Patents

Crystalline forms of 4- [2- (-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain

Info

Publication number
MY150698A
MY150698A MYPI20084894A MY150698A MY 150698 A MY150698 A MY 150698A MY PI20084894 A MYPI20084894 A MY PI20084894A MY 150698 A MY150698 A MY 150698A
Authority
MY
Malaysia
Prior art keywords
methylphenylsulfanyl
piperidine
phenyl
treatment
neuropathic pain
Prior art date
Application number
Inventor
Bang-Andersen Benny
Faldt André
Stensbøl Tine Bryan
Miller Silke
Lopez De Diego Heidi
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MY150698A publication Critical patent/MY150698A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

CRYSTALLINE FORMS OF 4-[2-(4-METHYLPHENYLSULFANYL)-PHENYL]PIPERIDINE AND SALTS THEREOF ARE PROVIDED E.G. FOR THE TREATMENT OF NEUROPATHIC PAIN. (FIGURE 23)
MYPI20084894 2006-06-16 2007-06-15 Crystalline forms of 4- [2- (-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain MY150698A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80500906P 2006-06-16 2006-06-16
DKPA200600816 2006-06-16
DKPA200700423 2007-03-20

Publications (1)

Publication Number Publication Date
MY150698A true MY150698A (en) 2014-02-28

Family

ID=39722478

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20084894 MY150698A (en) 2006-06-16 2007-06-15 Crystalline forms of 4- [2- (-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain

Country Status (15)

Country Link
JP (1) JP2014098017A (en)
KR (1) KR101472595B1 (en)
AR (1) AR061480A1 (en)
AT (1) ATE508115T1 (en)
BR (1) BRPI0712758A2 (en)
CA (1) CA2784304A1 (en)
DE (1) DE602007014372D1 (en)
DK (1) DK2044020T3 (en)
MY (1) MY150698A (en)
NZ (1) NZ572856A (en)
PT (1) PT2044020E (en)
RS (1) RS51687B (en)
SI (1) SI2044020T1 (en)
TN (1) TNSN08461A1 (en)
TW (1) TWI444365B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101972931B1 (en) 2017-10-19 2019-04-26 재단법인대구경북과학기술원 Balloon type ecog measuring device and its manufacturing method
CN116930385B (en) * 2023-08-08 2024-02-20 北京爱思益普生物科技股份有限公司 A method for determining the concentration of compounds in high-salt concentration preparations
CN117305360B (en) * 2023-09-15 2024-09-24 江南大学 A mammalian cell nuclear transfection solution and its preparation method and application in cell nucleus delivery

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (en) * 2001-10-04 2008-02-11 Х. Луннбек А/С Derivated of phenylpiperazine as serotonin reuptake inhibitorS
CA2656057C (en) * 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain

Also Published As

Publication number Publication date
DK2044020T3 (en) 2011-08-15
DE602007014372D1 (en) 2011-06-16
ATE508115T1 (en) 2011-05-15
NZ572856A (en) 2012-02-24
KR101472595B1 (en) 2014-12-15
TW200817329A (en) 2008-04-16
JP2014098017A (en) 2014-05-29
TWI444365B (en) 2014-07-11
RS51687B (en) 2011-10-31
CA2784304A1 (en) 2007-12-21
BRPI0712758A2 (en) 2012-09-25
KR20090018630A (en) 2009-02-20
PT2044020E (en) 2011-05-12
SI2044020T1 (en) 2011-06-30
TNSN08461A1 (en) 2010-04-14
AR061480A1 (en) 2008-08-27

Similar Documents

Publication Publication Date Title
IL195310A0 (en) Crystalline forms of 4-[2-(4-methylphenylsulfanyl)- phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
MY163537A (en) 4- [2- (4-methylphenylsulfanyl)phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistent depression or residual symptoms in depression
NO343929B3 (en) 1- [2- (2,4-dimethylphenylsulfanyl-phenyl] -piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5HT1A activity for the treatment of cognitive pain
IL192242A0 (en) Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides
NZ592543A (en) 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
SI2076501T1 (en) Crystalline forms of 3-(5-(2-fhjorophenyl)-(1,2,4)oxadiazol-3-yl)-benzoic acid
NZ700778A (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl} -1-methyl-urea and salts thereof.
MY147389A (en) Phthalazinone derivative
UA97392C2 (en) 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of pain
EP2358691B8 (en) Process for the preparation of piperazine compounds and hydrochloride salts thereof
MY150698A (en) Crystalline forms of 4- [2- (-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
PL1848700T3 (en) Salts of (s)-2-amino-3-{4-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-phenyl}-propionic acid and its methyl ester as interleukin inhibitors for the treatment of obesity or diabetes
EA201000611A1 (en) 4,4-DESIGNED PIPERIDINES
UA95801C2 (en) Crystalline forms of 4-[2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
PL382346A1 (en) The manner of production of salt of 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-ethenylo)phenylo)-3-(2-(1-hydroxy-1- methyloethylo)phenylo)propylo)sulphanylo)methylo)-cyclopropaiacetic acid
IL200959A0 (en) Liquid formulations of salts of 4-[2-(4-methylphenylfanyl)phenyl]piperidine
AU2008339005A8 (en) 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of Alzheimer's disease
EA201000720A1 (en) 4,4-DESIGNED PIPERIDINES AS RENIN INHIBITORS
BRPI0715711A2 (en) L-GLUTAMIC ACID PRODUCING BACTERIA, AND, METHODS FOR PRODUCING L-GLUTAMIC ACID, AND FOR IMPROVING THE GROWTH OF A L-GLUTAMIC ACID PRODUCING MICROORGANISM UNDER ACID CONDITIONS
AU2016202490A1 (en) 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
UA98676C2 (en) Zibotentan composition containing mannitol and/or microcrystalline cellulose
HK1145494A (en) 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
HK1146282A (en) 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1
WO2011029088A3 (en) Preparation of raloxifene and its salts
UA101005C2 (en) Therapeutic uses of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine for the treatment of depression associated with irritable bowel syndrome